These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22879203)

  • 41. Simultaneous determination of testosterone, 5alpha-androstan-17beta-ol-3-one, 5alpha-androstane-3alpha,17beta-diol and 5alpha-androstane-3beta,17beta-diol in plasma of adult male rabbits by radioimmunoassay(1).
    Schanbacher BD; Ewing LL
    Endocrinology; 1975 Oct; 97(4):787-92. PubMed ID: 1193006
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mass spectrometry of steroid glucuronide conjugates. II-Electron impact fragmentation of 3-keto-4-en- and 3-keto-5alpha-steroid-17-O-beta glucuronides and 5alpha-steroid-3alpha,17beta-diol 3- and 17-glucuronides.
    Thevis M; Opfermann G; Schmickler H; Schänzer W
    J Mass Spectrom; 2001 Sep; 36(9):998-1012. PubMed ID: 11599078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endogenous sex hormones and the risk of prostate cancer: a prospective study.
    Weiss JM; Huang WY; Rinaldi S; Fears TR; Chatterjee N; Hsing AW; Crawford ED; Andriole GL; Kaaks R; Hayes RB
    Int J Cancer; 2008 May; 122(10):2345-50. PubMed ID: 18172860
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
    Wiegratz I; Jung-Hoffmann C; Kuhl H
    Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis of new steroid haptens for radioimmunoassay. Part III. 15beta-Carboxyethylmercaptosteroid-bovine serum albumin conjugates. Specific antisera for radioimmunoassay of 5alpha-dihydrotestosterone, 5alpha-androstane-3beta, 17beta-diol and 5alpha-androstane-3alpha, 17beta-diol.
    Rao PN; Khan AH; Moore PH
    Steroids; 1977 Feb; 29(2):171-84. PubMed ID: 841620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.
    Murtola TJ; Gurel B; Umbehr M; Lucia MS; Thompson IM; Goodman PJ; Kristal AR; Parnes HL; Lippman SM; Sutcliffe S; Peskoe SB; Barber JR; Drake CG; Nelson WG; De Marzo AM; Platz EA
    Cancer Epidemiol Biomarkers Prev; 2016 Mar; 25(3):463-9. PubMed ID: 26715424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Circadian genes and risk of prostate cancer in the prostate cancer prevention trial.
    Chu LW; Till C; Yang B; Tangen CM; Goodman PJ; Yu K; Zhu Y; Han S; Hoque AM; Ambrosone C; Thompson I; Leach R; Hsing AW
    Mol Carcinog; 2018 Mar; 57(3):462-466. PubMed ID: 29318656
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial.
    Neuhouser ML; Platz EA; Till C; Tangen CM; Goodman PJ; Kristal A; Parnes HL; Tao Y; Figg WD; Lucia MS; Hoque A; Hsing AW; Thompson IM; Pollak M
    Cancer Prev Res (Phila); 2013 Feb; 6(2):91-9. PubMed ID: 23315596
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The influence of finasteride on the development of prostate cancer.
    Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
    N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
    Kristal AR; Till C; Platz EA; Song X; King IB; Neuhouser ML; Ambrosone CB; Thompson IM
    Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):638-46. PubMed ID: 21335507
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of steroidogenesis and steroidogenic enzyme functions.
    Luu-The V
    J Steroid Biochem Mol Biol; 2013 Sep; 137():176-82. PubMed ID: 23770321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced formation of non-phenolic androgen metabolites with intrinsic oestrogen-like gene transactivation potency in human breast cancer cells: a distinctive metabolic pattern.
    Pérez-Palacios G; Santillán R; García-Becerra R; Borja-Cacho E; Larrea F; Damián-Matsumura P; González L; Lemus AE
    J Endocrinol; 2006 Sep; 190(3):805-18. PubMed ID: 17003281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men.
    Rittmaster RS; Stoner E; Thompson DL; Nance D; Lasseter KC
    J Androl; 1989; 10(4):259-62. PubMed ID: 2550402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial.
    Nash SH; Till C; Song X; Lucia MS; Parnes HL; Thompson IM; Lippman SM; Platz EA; Schenk J
    Cancer Epidemiol Biomarkers Prev; 2015 Oct; 24(10):1507-15. PubMed ID: 26269564
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The determination of 5alpha-androstane-3alpha, 17beta-diol in human plasma by radioimmunoassay.
    Laband P; Tresguerres JA; Lisboa BP; Volkwein U; Tamm J
    Acta Endocrinol (Copenh); 1978 Aug; 88(4):778-86. PubMed ID: 581118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
    Tindall DJ; Rittmaster RS
    J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
    [TBL] [Abstract][Full Text] [Related]  

  • 58. V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk.
    Boger-Megiddo I; Weiss NS; Barnett MJ; Goodman GE; Chen C
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):286-91. PubMed ID: 18268111
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer.
    Peskoe SB; Joshu CE; Rohrmann S; McGlynn KA; Nyante SJ; Bradwin G; Dobs AS; Kanarek N; Nelson WG; Platz EA
    Prostate; 2015 Aug; 75(11):1167-76. PubMed ID: 25919471
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients.
    Melcangi RC; Santi D; Spezzano R; Grimoldi M; Tabacchi T; Fusco ML; Diviccaro S; Giatti S; Carrà G; Caruso D; Simoni M; Cavaletti G
    J Steroid Biochem Mol Biol; 2017 Jul; 171():229-235. PubMed ID: 28408350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.